Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
hormone receptor +
How you choose between letrozole or exemestane when patients have AIMSS with anastrozole in adjuvant breast cancer therapy?
Related Questions
How do you approach ovarian function suppression in premenopausal women with HR+/HER2-, node negative breast cancer and intermediate OncoType dx scores (11-25) who received chemotherapy?
Would you provide anthracycline-based therapy for early stage node negative triple-negative breast cancer in patient with echocardiogram showing grade 1 diastolic dysfunction?
How do you treat inflammatory breast cancer (HR+, HER2 1+) treated with NAC (ACT) and mastectomy, with multifocal subcentimeter residual disease that on retesting is HR+, HER 2 2+ FISH amplified?
Would you send Oncotype for pre-menopausal women with HR+, HER2(-) breast cancer with a small tumor (pT1b) and micrometastatic LN involvement or recommend adjuvant chemotherapy without sending Oncotype?
What would you recommend regarding HRT use in a patient with history of HR-, HER2+ breast cancer dealing with post-menopausal symptoms?
How do you manage steroid refractory pneumonitis due to docetaxel or trastuzumab?
Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?
Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?
Would you give adjuvant endocrine therapy to a premenopausal woman with early stage node positive breast cancer that was ER negative, PR positive (60%) and HER2 positive?
In which patients do you offer adjuvant bisphosphates in breast cancer treatment?
